Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

16 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Clinically validated mutation scores for HIV-1 resistance to fosamprenavir/ritonavir.
Masquelier B, Assoumou KL, Descamps D, Bocket L, Cottalorda J, Ruffault A, Marcelin AG, Morand-Joubert L, Tamalet C, Charpentier C, Peytavin G, Antoun Z, Brun-Vézinet F, Costagliola D; ANRS Resistance Study Group. Masquelier B, et al. Among authors: antoun z. J Antimicrob Chemother. 2008 Jun;61(6):1362-8. doi: 10.1093/jac/dkn127. Epub 2008 Apr 4. J Antimicrob Chemother. 2008. PMID: 18390885
Genotypic resistance analysis of the virological response to fosamprenavir-ritonavir in protease inhibitor-experienced patients in CONTEXT and TRIAD clinical trials.
Marcelin AG, Flandre P, Molina JM, Katlama C, Yeni P, Raffi F, Antoun Z, Ait-Khaled M, Calvez V. Marcelin AG, et al. Among authors: antoun z. Antimicrob Agents Chemother. 2008 Dec;52(12):4251-7. doi: 10.1128/AAC.00514-08. Epub 2008 Oct 13. Antimicrob Agents Chemother. 2008. PMID: 18852278 Free PMC article. Clinical Trial.
Comparison of metabolic abnormalities 48 weeks after switching from highly active antiretroviral therapy containing a non-nucleoside reverse transcriptase inhibitor to Trizivir versus continued highly active antiretroviral therapy.
Katlama C, Gazzard B, Mallolas J, Schürmann D, Moroni M, Demonty N, Antoun Z, Gordon D. Katlama C, et al. Among authors: antoun z. AIDS. 2003 Aug 15;17(12):1855-6. doi: 10.1097/00002030-200308150-00017. AIDS. 2003. PMID: 12891074 Clinical Trial.
Comparison of metabolic abnormalities and clinical lipodystrophy 48 weeks after switching from HAART to Trizivir versus continued HAART: the Trizal study.
Lafeuillade A, Clumeck N, Mallolas J, Jaeger H, Livrozet JM, Ferreira Mdo S, Johnson M, Cheret A, Antoun Z; European Trizal team. Lafeuillade A, et al. Among authors: antoun z. HIV Clin Trials. 2003 Jan-Feb;4(1):37-43. doi: 10.1310/ejrf-jggh-grcd-med8. HIV Clin Trials. 2003. PMID: 12577195 Clinical Trial.
Efficacy and safety of once-daily fluticasone furoate/vilanterol (FF/VI) versus twice-daily inhaled corticosteroids/long-acting β2-agonists (ICS/LABA) in patients with uncontrolled asthma: An open-label, randomized, controlled trial.
Devillier P, Humbert M, Boye A, Zachgo W, Jacques L, Nunn C, West S, Nicholls A, Antoun Z, Spinu L, Grouin JM. Devillier P, et al. Among authors: antoun z. Respir Med. 2018 Aug;141:111-120. doi: 10.1016/j.rmed.2018.06.009. Epub 2018 Jun 9. Respir Med. 2018. PMID: 30053956 Free article. Clinical Trial.
Collections d’échantillons biologiques humains pour la recherche : principaux enjeux et conséquences pour le patient ?
Verstuyft C, Antoun Z, Deplanque D; les participants à la table ronde « Recherche clinique et méthodologie » des Ateliers de Giens XXXIII. Verstuyft C, et al. Among authors: antoun z. Therapie. 2018 Feb;73(1):63-72. doi: 10.1016/j.therap.2017.12.003. Epub 2017 Dec 19. Therapie. 2018. PMID: 29433746 French. No abstract available.
16 results